1. Scrip
  2. >>Business
  3. >>Strategy

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

 
• By Joseph Haas

Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.

New direction
Cidara divests its antifungal and unveils a new corporate direction • Source: Shutterstock

Cidara Therapeutics, Inc. took a series of steps 24 April that completely reinvent the company, essentially forming a new company with a new focus, Cidara CEO Jeffrey Stein said in an interview.

Key Takeaways

  • Cidara is switching tracks, offloading all rights to antifungal Rezzayo to partner Mundipharma while reacquiring a universal flu-prevention candidate from Janssen.

  • The biotech raised a $240m private placement that it says will fund advancement of the flu candidate CD388 through a Phase IIb trial

About a year after obtaining US Food and Drug Administration approval for its antifungal Rezzayo (rezafungin), Cidara announced it is offloading the novel echinocandin to India’s Mundipharma International Limited and reacquiring an influenza prevention candidate it licensed out to Janssen Pharmaceuticals Inc. in 2021

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.